29th August 2026, A/Prof Chee L Khoo
The European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause recommend that a holistic approach is taken for women during perimenopause and menopause, not having a sole focus on hormone replacement therapy (HRT)/ menopausal hormone therapy (MHT) (1). It recognised that these women can be appropriately managed in primary care according to recognised guidelines.…
31st October 2025, A/Prof Chee L Khoo
We have covered the issue of lipoprotein (a) on a number of occasions in the past. We highlighted how the additional atherosclerotic harm in patients with elevated levels. Although lipoprotein (a) lowering agents are yet to hit the market, it is still important to check the levels at least once in all patients as the results may influence your LDL-C targets as well as prompt further cardiovascular investigations.…
30th June 2024, A/Prof Chee L Khoo
We advocate applying protective sunscreens for little babies onwards because most of the sun damage starts from young and often, we fight a losing battle trying to rescue severe sun damaged skin in later life. It wouldn’t be any different in dyslipidaemia in children and adults. When you think about it, it really doesn’t matter what age you are.…
13th October 2022, Dr Chee L Khoo
Obesity, type 2 diabetes mellitus (T2D), fatty liver disease, and cardiovascular disease (CVD) are complex and very inter-related cardio-metabolic conditions. Most of these conditions have lipids derangements as a major contributor to complications. While the link between lipids, in particular LDL-C, and CVD is linear and robust, there is still residual risks after aggressive treatment with lipid lowering agents.…
26th June 2022, Dr Chee L Khoo
I was recently tasked with preparing a lecture on the current guidelines for lipid management in patients with diabetes. I thought it was quite straight forward. We have known for some years now that the targets are tighter than patients without diabetes. Thus, it can’t be that hard. As I looked into national and international guidelines, they started to get more and more complicated.…
13th November 2021, Dr Chee L Khoo
The authority to prescribe a PCSK9 inhibitors for patients with resistant hyperlipidaemia under the PBS continues to be pretty complicated. We tried to simplified those numerous criteria back in December 2020 here when the criteria were “loosened” somewhat. This has facilitated my prescription of this important drug in those patients who have really, really high cardiovascular risk.…
24th October 2021, Dr Chee L Khoo
Last fortnight we explored the disease burden in patients who have high lipids from a very young age and the effect on their future cardiovascular risk. This consideration allows us to think about who should be aggressively treated and whom we can just safely watch, at least for a few years. It would be nice to be able identify who we should screen for high lipids from a young age so that we can start lifestyle measures early.…
2nd October 2021, Dr Chee L Khoo
We generally see two categories of patients with high lipids, one who had normal lipids earlier on in life but developed high lipids later in life because of modern living and one whose lipids were already high when they were young (and slim and fit). Most of the scientific studies linking high lipids with cardiovascular (CV) events look at lipid levels at a snap point in time, at enrolment and the follow up period just aren’t long enough.…